Comparative study on the level of glycosylated hemoglobin in patients with diabetes treated with actrapid monotard analog or actrapid monotard
10.3760/cma.j.issn.1673-4904.2011.04.006
- VernacularTitle:人胰岛素类似物与人胰岛素减低糖化血红蛋白水平的比较研究
- Author:
Hui XU
- Publication Type:Journal Article
- Keywords:
Insulin;
Hemoglobin A,glycosylated;
Insulin analog
- From:
Chinese Journal of Postgraduates of Medicine
2011;34(4):17-19
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the level of glycosylated hemoglobin (HbA1c) in patients with diabetes treated with actrapid monotard analog or actrapid monotard. Methods One hundred and twenty patients with type 2 diabetes were divided into actrapid monotard analog group and actrapid monotard group with 60 cases in each by admission number. Fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPBG), HbA1c were obtained and analyzed. Results The overall cure rate were similar between actrapid monotard analog group and actrapid monotard group (83.3%, 50/60 vs. 86.7%, 52/60, P ＞ 0.05 ). There was no significant difference in FBG, 2hPBG before treatment between two groups (P ＞ 0.05),but there was significant difference at 2 weeks after treatment between two groups (P ＜ 0.05 ) . There was no significant difference in HbA1c before treatment between two groups (P＞ 0.05 ) ,but there was significant difference at 3 months after treatment between two groups (P ＜ 0.05 ). FBG, 2hPBG, HbA1c after treatment were improved compared with before treatment in two groups (P ＜ 0.05 ). Conclusion Actrapid monotard analog provides better blood glucose control compare with actrapid monotard while providing the convenience of injecting immediately before meals.
